- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03051906
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer (DUCRO-HN)
November 20, 2017 updated by: Lorenzo Livi, Azienda Ospedaliero-Universitaria Careggi
Anti PD-L1 Durvalumab Combined With Cetuximab and Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Phase I/II Study
In over 60% of cases, squamous cell carcinoma of the head and neck (SCCHN) is discovered at a loco-regionally advanced stage that requires a combined multimodal strategy in order to pursue a curative intent.
Bonner et al demonstrated that the combination of radiation (RT) with Cetuximab (CTX), a chimeric mouse IgG1 monoclonal anti-EGFR antibody, results in better median locoregional control and overall survival compared with RT alone without an increased rate of > G3 acute toxicity or detrimental effect on compliance and quality of life.
However, subsequent negative trials (RTOG 0522) led to the hypothesis that in unselected patient populations the benefit of CTX may be diluted due to the molecular heterogeneity of SSCHN.
Moreover, the absence of biomarkers predictive of response to anti-EGFR treatment may in part be explained by the observation that other factors play a role in favoring its anticancer effect, namely immunologic mechanisms.
It has been demonstrated that SCCHN is an immunosuppressive disease characterized by prominent immuno-escape mechanisms, such as induction of a tumor-permissive cytokine profile and qualitative/quantitative lymphocyte deficiencies, occurrence of anergy in major immune effector cells and poor antigen presentation.
Given these observations, it has been postulated that SCCHN may benefit from immunotherapeutic strategies, primarily aimed at PD-L1/PD1 checkpoint blockade.
Segal et al (Asco 2015) reported preliminary results on the use of Durvalumab in pretreated patients with recurrent/metastatic SCCHN.
Durvalumab is a humanized monoclonal IgG1 antibody that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity, thereby promoting activity of tumor-specific effector T cells and global anti-tumor immune response.
Out of 64 treated patients, 51 patients were available for the preliminary efficacy analysis: promisingly, the overall response rate was 12% (25% in PD-L1 positive patients).
To date, no clinical trial, specifically designed for SCCHN, testing PD-L1 targeted agents has been completed, nor have been initiated combination strategies of CTX, RT and PD1/PD-L1 antibodies in the curative setting.
Taken all data together, a strong rationale may support the combination of Durvalumab, anti-EGFR therapy such as CTX and RT in order to revert the SCCHN-induced immune suppression and maximize treatment efficacy, ultimately through enhanced, CTX-mediated immune mechanisms and maximized RT-specific cytotoxicity.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
69
Phase
- Phase 2
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent and any locally-required authorization obtained from the patients prior to performing any protocol-related procedures, including screening evaluations
- Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx, hypopharynx and larynx
- For patients with oropharyngeal cancer only: confirmed HPV status by HPV- DNA ISH prior to registration
- Confirmed PD-L1-positive or -negative status by the Ventana SP263 IHC assay
- Patients agree to provide their smoking history prior to registration
- Clinical stage of HPV-negative oropharynx and all hypopharynx and larynx: T1-2, N2a-N3 or T3-4, any N (AJCC 7th ed.), including no distant metastases
- Clinical stage of HPV-positive oropharynx: T2-4, N2b-N3 (AJCC 7th ed.), including no distant metastases with smoking history ≥ 10 pack/years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate bone marrow: absolute neutrophil count ≥ 1,500/μl, platelets ≥ 100,000/μl, hemoglobin ≥ 9 g/dL
- Adequate hepatic function: total bilirubin ≤ 1.5 X upper normal limit (UNL), aspartate aminotransferase (AST) ≤ 2.5 X UNL, alanine aminotransferase (ALT) ≤ 2.5 X UNL
- Adequate renal function: calculated serum creatinine clearance >40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection
Exclusion Criteria:
- Histologically confirmed head and neck cancer of any other primary anatomic location in the head and neck not specified in the inclusion criteria including patients with SCCHN of unknown primary or non-squamous histologies (eg, nasopharynx or salivary gland)
- Clinical stage of HPV-negative oropharynx and all hypopharynx and larynx: T1-2, N0-1 (AJCC 7th ed.)
- Clinical stage of HPV-positive oropharynx: T1-2, N0-N2a (AJCC, 7th ed.) or any T, any N with smoking history of < 10 pack/years
- History of another primary malignancy except for: malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study drug and of low potential risk for recurrence; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated carcinoma in situ without evidence of disease (eg, carcinoma in situ of the breast, oral cavity and cervix are all permissible); low risk prostate cancer based on NCCN criteria on active surveillance, not candidate to any curative treatment given the extremely low likelihood of disease progression
- Gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease
- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- Prior use of cetuximab or other anti-EGFR therapy
- Any previous treatment with PD-1 or PD-L1 inhibitors, including Durvalumab
- Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Frediricia's Correction
- Current or prior use of immunosuppressive medication within 28 days before the first dose of Durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
- Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy
- Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
- Active or prior documented autoimmune disease within the past 2 years (subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment within the past 2 years are not excluded)
- Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- History of primary immunodeficiency
- History of allogeneic organ transplant
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- Severe, active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days of registration
- Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
- Known history of active infection including tuberculosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
|
Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the efficacy of the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
Time Frame: 2-year PFS
|
Progression-free survival according to Recist 1.1
|
2-year PFS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess the number of participants with treatment-related adverse events according to CTCAE v.4
Time Frame: Within 90 days of end of treatment (last infusion of Durvalumab scheduled at 29th week; EoT)
|
Acute toxicity according to CTCAE v. 4
|
Within 90 days of end of treatment (last infusion of Durvalumab scheduled at 29th week; EoT)
|
To assess the tolerability of the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
Time Frame: Within 90 days of end of treatment (last infusion of Durvalumab scheduled at 29th week; EoT)
|
Relative dose intensity (RDI) of Durvalumab, Cetuximab and Radiotherapy
|
Within 90 days of end of treatment (last infusion of Durvalumab scheduled at 29th week; EoT)
|
To assess the efficacy of the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
Time Frame: 2-year LRC
|
Locoregional control (LRC) according to Recist 1.1
|
2-year LRC
|
To assess the efficacy of the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
Time Frame: 2-year OS
|
Overall Survival (OS) according to Recist 1.1
|
2-year OS
|
To assess the efficacy of the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
Time Frame: 5-year OS
|
Overall Survival (OS) according to Recist 1.1
|
5-year OS
|
To assess the number of participants with treatment-related adverse events
Time Frame: Beyond 90 days of end of treatment (last infusion of Durvalumab scheduled at 29th week; EoT)
|
Late toxicity according to CTCAE v.4
|
Beyond 90 days of end of treatment (last infusion of Durvalumab scheduled at 29th week; EoT)
|
To assess health-related quality of life (HRQoL) in patients treated with the experimental regimen (Durvalumab, Cetuximab and Radiotherapy)
Time Frame: Baseline, within 2 weeks of end of treatment (EoT), 12 months (change over time)
|
EORTC-QLQ C30, EORTC-QLQ H&N35 questionnaires
|
Baseline, within 2 weeks of end of treatment (EoT), 12 months (change over time)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Bonomo P, Desideri I, Mangoni M, Saieva C, Loi M, Becherini C, Cerbai C, Ganovelli M, Salvestrini V, Stocchi G, Zani M, Palomba A, Livi L. Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase 1/2 trial. Radiother Oncol. 2022 Apr;169:64-70. doi: 10.1016/j.radonc.2022.02.008. Epub 2022 Feb 11.
- Bonomo P, Desideri I, Loi M, Mangoni M, Sottili M, Marrazzo L, Talamonti C, Greto D, Pallotta S, Livi L. Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO). Clin Transl Radiat Oncol. 2018 Feb 7;9:42-47. doi: 10.1016/j.ctro.2018.01.005. eCollection 2018 Feb. Erratum In: Clin Transl Radiat Oncol. 2021 Jan 29;27:96-97.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2018
Primary Completion (Anticipated)
January 1, 2022
Study Completion (Anticipated)
January 1, 2025
Study Registration Dates
First Submitted
February 6, 2017
First Submitted That Met QC Criteria
February 9, 2017
First Posted (Actual)
February 14, 2017
Study Record Updates
Last Update Posted (Actual)
November 22, 2017
Last Update Submitted That Met QC Criteria
November 20, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DUCRO-HN
- 2016-004668-20 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Clinical and biologic (translational) individual data will be available after the end of study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on Durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
Hark Kyun KimRecruiting
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
MedImmune LLCCompletedAdvanced Solid TumorsUnited States, France, Spain, Switzerland
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
AstraZenecaCompleted